Long-term Immunogenicity Study of Herpes Zoster Subunit Vaccine (GSK1437173A) and Immunogenicity and Safety Assessment of Revaccination With Two Additional Doses in Adults With Renal Transplant From Study ZOSTER-041
Latest Information Update: 12 Aug 2024
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Pharmacodynamics
- Acronyms ZOSTER-073 EXT:041 Y4-10
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
Most Recent Events
- 10 Aug 2024 This trial has been completed in Belgium (Global end date: 5 Aug 2024).
- 25 Apr 2024 This trial has been completed in Finland, according to European Clinical Trials Database record.
- 14 Nov 2022 Planned End Date changed from 8 Apr 2024 to 14 Aug 2024.